Dr. Steven Wagner PhD is a Professor in the Department of Neurosciences at UCSD. He has spent over 25 years in the biopharmaceutical industry, and more recently in academia studying translational neuroscience of age-related neurodegenerative disorders with an emphasis on Alzheimer’s disease (AD). He led the team that discovered the first non-NSAID-like and truly “Notch-sparing” gamma-secretase modulators and introduced the term “gamma-secretase modulators” (GSMs) in 2005 through the discovery of a novel series of diaryl-2-aminothiazole derivatives that are over 5000-fold more potent at lowering A42 levels than the NSAID-like “substrate-targeted” gamma-secretase modulators, e.g., tarenflurbil. His team also, for the first time, purified to homogeneity the gamma-secretase enzyme complex that is ultimately responsible for generating amyloid β(Aβ) plaques, the diagnostic hallmark of AD. Since moving back to academia, into the Department of Neurosciences at UCSD in June of 2009, his laboratory, in addition to designing/discovering another novel and structurally distinct GSM chemotype, was awarded a Blueprint Neurotherapeutics U01 by NIH/NINDS (one of only seven issued in all of Neurology) to optimize and develop GSMs for the treatment and/or prevention of AD. He is also a member of the NIH Drug Discovery SBIR (ETTN-M)ETTN IRG, Division of Neuroscience, Development and Aging Study Section, a member of the NINDS Special Emphasis Panel for the Blueprint Neurotherapeutics Network, as well as a member of the Cure Alzheimer’s Fund (CAF) Research Consortium and the Scientific Advisory Board for the Alzheimer’s Association’s Collaboration for Cure (C4C).